Prediction of abstinence in opioid-dependent patients

Journal of Addiction Medicine

Volumn 2, Issue 4, 2008, Pages 194-201

  Dijkstra, Boukje A G ^a,b,d   De Jong, Cor A J ^a,b   Krabbe, Paul F M ^c   Van Der Staak, Cees P F ^b  

^a Novadic Kentron   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NISPA   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349269249     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31818a6596     Document Type: Article

References (47)

1. EMCDDA. Annual Report 2007: The State of the Drugs Problem in Europe. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2007.
2. Mark TL, Woody GE, Juday T, et al. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001;61:195-206.
3. Critchlow G, Nadeem H. Abstinence-oriented treatment for opiate addiction [author reply]. Br J Psychiatry. 2006;188:292-293.
4. Dyer C. Addict died after rapid opiate detoxification. BMJ. 1998;316: 170.
5. Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2006; CD001333.
6. Rabinowitz J, Cohen H, Tarrasch R, et al. Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug Alcohol Depend. 1997;47:77-86.
7. Anton RF, Hogan I, Jalali B, et al. Multiple family therapy and naltrexone in the treatment of opiate dependence. Drug Alcohol Depend. 1981;8:157-168.
8. Hulse GK, Basso MR. The association between naltrexone compliance and daily supervision. Drug Alcohol Rev. 2000;19:41-48.
9. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;101:491-503.
10. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet. 1995;345:1616-1619.
11. Gollnisch G. Multiple predictors of illicit drug use in methadone maintenance clients. Addict Behav. 1997;22:353-366.
12. Marsch LA, Stephens MA, Mudric T, et al. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Exp Clin Psychopharmacol. 2005;13:293-302.
13. Termorshuizen F, Krol A, Prins M, et al. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend. 2005;79:231-240.
14. Cacciola JS, Alterman AI, Rutherford MJ, et al. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend. 2001;61:271-280.
15. de Weert-van Oene GH, Burger H, Grobbee DE, et al. Identification of patients at high risk of noncompliance in substance dependence treatment. Eur Addict Res. 2007;13:74-80.
16. Franken IH, Hendriks VM. Predicting outcome of inpatient detoxification of substance abusers. Psychiatr Serv. 1999;50:813-817.
17. Baekeland F, Lundwall L. Dropping out of treatment: a critical review. Psychol Bull. 1975;82:738-783.
18. Backmund M, Meyer K, Eichenlaub D, et al. Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients. Drug Alcohol Depend. 2001;64:173-180.
19. Shufman EN, Porat S, Witztum E, et al. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry. 1994; 35:935-945.
20. Lerner A, Sigal M, Bacalu A, et al. A naltrexone double blind placebo controlled study in Israel. Isr J Psychiatry Relat Sci. 1992;29:36-43.
21. Bradley BP, Phillips G, Green L, et al. Circumstances surrounding the initial lapse to opiate use following detoxification. Br J Addiction. 1989;154:354-359.
22. Gossop M, Green L, Phillips G, et al. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry. 1989;154:348-353.
23. Greenstein RA, Evans BD, McLellan AT, et al. Predictors of favorable outcome following naltrexone treatment. NIDA Res Monogr. 1983;43: 294-301.
24. McGregor C, Ali R, White JM, et al. A comparison of antagonist- precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug Alcohol Depend. 2002;68: 5-14.
25. Rabinowitz J, Cohen H, Kotler M. Outcomes of ultrarapid opiate detoxification combined with naltrexone maintenance and counseling. Psychiatr Serv. 1998;49:831-833.
26. Roozen HG, Kerkhof AJ, van den Brink W. Experiences with an outpatient relapse program (community reinforcement approach) combined with naltrexone in the treatment of opioid-dependence: effect on addictive behaviors and the predictive value of psychiatric comorbidity. Eur Addict Res. 2003;9:53-58.
27. Gossop M, Green L, Phillips G, et al. Factors predicting outcome among opiate addicts after treatment. Br J Clin Psychol. 1990;29(part 2):209-216.
28. Lawental E. Ultra rapid opiate detoxification as compared to 30-day inpatient detoxification program-a retrospective follow-up study. J Subst Abuse. 2000;11:173-181.
29. Gossop M, Green L, Phillips G, et al. What happens to opiate addicts immediately after treatment: a prospective follow up study. Br Med J (Clin Res Ed). 1987;294:1377-1380.
30. Haro G, Mateu C, Martinez-Raga J, et al. The role of personality disorders on drug dependence treatment outcomes following inpatient detoxification. Eur Psychiatry. 2004;19:187-192.
31. Powell J, Dawe S, Richards D, et al. Can opiate addicts tell us about their relapse risk? Subjective predictors of clinical prognosis. Addict Behav. 1993;18:473-490.
32. Broers B, Giner F, Dumont P, et al. Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend. 2000;58: 85-92.
33. Islam R. Relapse following withdrawal of drug addiction. Br J Psychiatry. 1993;163:699.
34. De Jong CAJ, Laheij RJ, Krabbe PFM. General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomized controlled trial. Addiction. 2005;100:206-215.
35. De Jong CAJ, Roozen HG, van Rossum LG, et al. High abstinence rates in heroin addicts by a new comprehensive treatment approach. Am J Addict. 2007;16:124-130.
36. Kokkevi A, Hartgers C. EuropASI: European Adaptation of a Multidimensional Assessment Instrument for Drug and Alcohol Dependence. Eur Addict Res. 1995;4:208-211.
37. Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13:293-308.
38. Dijkstra BA, Krabbe PF, Riezebos TG, et al. Psychometric evaluation of the Dutch version of the Subjective Opiate Withdrawal Scale (SOWS). Eur Addict Res. 2007;13:81-88.
39. Arrindell WA, Ettema JHM. Klachtenlijst SCL-90 (Symptom Checklist- 90). The Netherlands: Lisse: Swets Test Services; 1986.
40. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30:473-483.
41. Franken IH, Hendriks VM, van den Brink W. Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict Behav. 2002;27:675-685.
42. Pfohl B, Blum N, Zimmerman M. Structured Interview for DSM-IV Personality Disorders (SIDP-IV). Washington DC: American Psychiatric Press, Inc; 1997.
43. Damen KF, De Jong CA, van der Kroft PJ. Interrater reliability of the structured interview for DSM-IV personality in an opioid-dependent patient sample. Eur Addict Res. 2004;10:99-104.
44. Damen KF, De Jong CA, Breteler MH, et al. Construct validity of the SIDP-IV in an opioid-dependent patient sample. JSubst Use. 2005;10:1-9.
45. Smyth BP, Barry J, Lane A, et al. In-patient treatment of opiate dependence: medium-term follow-up outcomes. Br JPsychiatry. 2005; 187:360-365.
46. Knapen LJ, Van gogh MT, Carpentier PJ, et al. Niet met methadon alleen [Not only methadone. A clinical epidemiologic study on psychiatric comorbidity and comorbid addiction in patients with opioid dependent patients during methadone maintenance treatment.]. The Netherlands: Sint-Oedenrode: Novadic-Kentron; 2007.
47. van den Brink W, Hendriks VM, Blanken P, et al. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327:310.